🇺🇸 FDA
Pipeline program

BIIB059

230LE305

Phase 3 small_molecule active

Quick answer

BIIB059 for 1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus Erythematosus is a Phase 3 program (small_molecule) at Biogen Idec Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Biogen Idec Ltd
Indication
1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus Erythematosus
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials